L. E. Shepherd

1.1k citations

43 papers · 800 indexed · h-index 15

Impact in

Cancer Research top 10%
- Breast Cancer Treatment Studies
Oncology top 5%
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Cancer Risks and Factors
- Viral-associated cancers and disorders

Papers in ⓘ

Cancer Research 22
- Breast Cancer Treatment Studies 21
Oncology 28
- Cancer Treatment and Pharmacology 15
- Colorectal Cancer Treatments and Studies 3
- Bone health and treatments 3

Co-authors: J. N. Ingle (10 shared papers)Dongsheng Tu (12 shared papers)H. B. Muss (5 shared papers)Michael Palmer (5 shared papers)Kathleen I. Pritchard (14 shared papers)Nicholas J. Robert (4 shared papers)Silvana Martino (4 shared papers)Stephen Couban (4 shared papers)
Journals: Journal of Clinical Oncology (23 papers)Annals of Oncology (6 papers)Cancer Research (4 papers)Blood (3 papers)Cancers (1 paper)
Partner nations: Canada United States Belgium

In The Last Decade

L. E. Shepherd

40 papers receiving 774 citations

Peers

Countries citing papers authored by L. E. Shepherd

Since Specialization

Citations

This map shows the geographic impact of L. E. Shepherd's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by L. E. Shepherd with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites L. E. Shepherd more than expected).

Fields of papers citing papers by L. E. Shepherd

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by L. E. Shepherd. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by L. E. Shepherd. The network helps show where L. E. Shepherd may publish in the future.

Co-authors

The 25 scholars most cited alongside L. E. Shepherd, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with L. E. Shepherd Line = papers co-authored together L. E. Shepherd links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 43 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Competing Causes of Death From a Randomized Trial of Extended Adjuvant Endocrine Therapy for Breast Cancer JNCI Journal of the National Cancer Institute ·J-AW Chapman, D. Meng, L. E. Shepherd, W.R. Parulekar, J. N. Ingle, H. B. Muss, Michael Palmer, C. Yu, P. E. Goss	2008	135
2	Gemcitabine, dexamethasone and cisplatin is an active andnon-toxic chemotherapy regimen in relapsed or refractory Hodgkin’s disease: a phase II study by the National Cancer Institute of Canada Clinical Trials Group Annals of Oncology ·Tara Baetz, Andrew R. Belch, Stephen Couban, Kevin Imrie, J. Yau, Robert E. Myers, Keyue Ding, Narinder Paul, L. E. Shepherd, José Iglesias, Ralph M. Meyer, Michael Crump	2003	120
3	Updated analysis of the NCIC CTG MA.17 randomized placebo (P) controlled trial of letrozole (L) after five years of tamoxifen in postmenopausal women with early stage breast cancer Journal of Clinical Oncology ·Paul E. Goss, J. N. Ingle, Silvana Martino, Nicholas J. Robert, H. B. Muss, Martine Piccart, Monica Castiglione, Dongsheng Tu, L. E. Shepherd, Joseph L. Pater	2004	63
4	Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA17 trial of extended adjuvant letrozole Annals of Oncology ·Paul E. Goss, J. N. Ingle, Silvana Martino, Nicholas J. Robert, Hyman B. Muss, Robert B. Livingston, Nancy E. Davidson, Edith A. Perez, Yanin Chávarri-Guerra, David Cameron, Kathleen I. Pritchard, Timothy J. Whelan, L. E. Shepherd, Dongsheng Tu	2012	60
5	Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17 Annals of Oncology ·J. N. Ingle, Dongsheng Tu, Joseph L. Pater, Hyman B. Muss, Silvana Martino, Nicholas J. Robert, Martine Piccart, M. Castiglione, L. E. Shepherd, Kathleen I. Pritchard, Robert B. Livingston, Nancy E. Davidson, Larry Norton, Edith A. Perez, Jeffrey S. Abrams, David Cameron, Michael Palmer, Paul E. Goss	2008	46
6	Specific Active Immunotherapy for Melanoma Annals of Surgery ·Hilliard F. Seigler, Edwin B. Cox, F Mutzner, L. E. Shepherd, Emma Nicholson, William W. Shingleton	1979	43
7	A meta-analysis of two randomised trials of early chemotherapy in asymptomatic metastatic colorectal cancer British Journal of Cancer ·Stephen P. Ackland, Michael Jones, Dongping Tu, John Simes, Jenny Chan Yuen, Sargeant Am, Haryana M. Dhillon, Goldberg Rm, Ehtesham Abdi, L. E. Shepherd, Moore Mj	2005	41
8	Randomized Trial of High-Dose Chemotherapy With Autologous Peripheral-Blood Stem-Cell Support Compared With Standard-Dose Chemotherapy in Women With Metastatic Breast Cancer: NCIC MA.16 Journal of Clinical Oncology ·Michael Crump, Stefan Glück, Dongsheng Tu, D. Stewart, Mark N. Levine, Peter Kirkbride, Janet Dancey, Séamus O’Reilly, Tsiporah B. Shore, Stephen Couban, Caroline Girouard, Susan Marlin, L. E. Shepherd, Kathleen I. Pritchard	2007	40
9	Clinical outcomes of ethnic minority women in MA.17: a trial of letrozole after 5 years of tamoxifen in postmenopausal women with early stage breast cancer Annals of Oncology ·Beverly Moy, Dongsheng Tu, Joseph L. Pater, J. N. Ingle, L. E. Shepherd, Timothy J. Whelan, Paul E. Goss	2006	26
10	Prognostic and predictive value of topoisomerase II alpha in a randomized trial comparing CMF to CEF in premenopausal women with node positive breast cancer (NCIC CTG MA.5) Journal of Clinical Oncology ·F. O’Malley, Stephen Chia, Dongsheng Tu, L. E. Shepherd, Mark N. Levine, David G. Huntsman, V. Bramwell, Irene L. Andrulis, Kathleen I. Pritchard	2006	26
11	Updated analysis of the NCIC CTG MA.17 randomized placebo (P) controlled trial of letrozole (L) after five years of tamoxifen in postmenopausal women with early stage breast cancer Journal of Clinical Oncology ·Paul E. Goss, J. N. Ingle, Silvana Martino, Nicholas J. Robert, H. B. Muss, Martine Piccart, Monica Castiglione, Dongsheng Tu, L. E. Shepherd, Joseph L. Pater	2004	23
12	A randomized trial of high-dose chemotherapy (HDCT) with autologous peripheral blood stem cell support (asct) compared to standard chemo therapy (ct) in women with metastatic breast cancer: a National Cancer Institute of Canada (NCIC) clinical trials group study European Journal of Cancer ·Stefan Glück, Michael Crump, D. Stewart, MN Levine, K. Pritchard, K. Paul Kirkbride, Janet Dancey, Séamus O’Reilly, Tsiporah B. Shore, Stephen Couban, Caroline Girouard, H. Abuzara, Dongping Tu, Sébastien Marlin, L. E. Shepherd	2001	21
13	Disease-free survival (DFS) vs. overall survival (OS) as a primary endpoint for adjuvant colon cancer studies: Individual patient data from 12,915 patients on 15 randomized trials Journal of Clinical Oncology ·Daniel J. Sargent, Sam Wieand, Jacqueline Benedetti, Roberto Labianca, Daniel G. Haller, L. E. Shepherd, J. F. Seitz, Guido Francini, Armand de Gramont, Richard M. Goldberg	2004	18
14	Serum 1-OH vitamin D (D) and prognosis of postmenopausal breast cancer (BC) patients: NCIC-CTG MA14 trial Journal of Clinical Oncology ·Esther Piura, J. W. Chapman, Allan Lipton, Li Zhu, Kim Leitzel, C. Wilson, Kathleen I. Pritchard, L. E. Shepherd, Michaël Pollak	2009	15
15	NCIC CTG MA.17: Intent to treat analysis (ITT) of randomized patients after a median follow-up of 54 months Journal of Clinical Oncology ·J. Ingle, Dongping Tu, L. E. Shepherd, Michael Palmer, Pater Jl, PE Goss	2006	14
16	Predicting survival with health-related quality of life scores in locally advanced breast cancer: Results from an international randomized controlled trial Journal of Clinical Oncology ·Fabio Efficace, P. Therasse, M. Piccart, Corneel Coens, Kristel Van Steen, Marzena Wełnicka-Jaśkiewicz, T. Čufer, M. Lichinitser, L. E. Shepherd, Andrew Bottomley	2004	13
17	NCIC-CTG MA14 Trial: Tamoxifen (tam) vs. tam + octreotide (oct) for adjuvant treatment of stage I or II postmenopausal breast cancer Journal of Clinical Oncology ·Michaël Pollak, J. W. Chapman, Kathleen I. Pritchard, James E. Krook, Harpal S. Dhaliwal, Ted Vandenberg, B. Norris, Timothy J. Whelan, C. Wilson, L. E. Shepherd	2008	12
18	Disease-free survival (DFS) vs. overall survival (OS) as a primary endpoint for adjuvant colon cancer studies: Individual patient data from 12,915 patients on 15 randomized trials Journal of Clinical Oncology ·Daniel J. Sargent, Sam Wieand, Jacqueline Benedetti, Roberto Labianca, Daniel G. Haller, L. E. Shepherd, J. F. Seitz, Guido Francini, Armand de Gramont, Richard M. Goldberg	2004	9
19	A dose escalation trial of adjuvant cyclophosphamide and epirubicin in combination with 5-fluorouracil using G-CSF support for premenopausal women with breast cancer involving four or more positive nodes Annals of Oncology ·B. Findlay, Katia Tonkin, Michael Crump, B. Norris, Maureen Trudeau, Martin E. Blackstein, Margot J. Burnell, Jamey Skillings, David M. J. S. Bowman, David Walde, Michelle S. Levine, Kathleen I. Pritchard, Michael Palmer, Dongsheng Tu, L. E. Shepherd	2007	8
20	Triple-negative receptor status and prognosis in the NCIC CTG MA. 21 adjuvant breast cancer trial Journal of Clinical Oncology ·Margot J. Burnell, Eibhlís M. O’Connor, Judith‐Anne W. Chapman, Mark N. Levine, Kathleen I. Pritchard, P. O’Brien, Kimberly Howarth, Zhen Ding, Timothy J. Whelan, L. E. Shepherd	2008	8

About L. E. Shepherd

L. E. Shepherd is a scholar working on Cancer Research, Oncology, Genetics, Pulmonary and Respiratory Medicine and Biological Psychiatry, having authored 43 papers that have together received 800 indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (21 papers), Cancer Treatment and Pharmacology (15 papers), Estrogen and related hormone effects (15 papers), Advanced Breast Cancer Therapies (10 papers), Colorectal Cancer Treatments and Studies (3 papers), Lymphoma Diagnosis and Treatment (3 papers), Bone health and treatments (3 papers) and Genetic factors in colorectal cancer (2 papers). The work is most often cited by research in Cancer Research (307 citations), Oncology (534 citations), Pathology and Forensic Medicine (185 citations), Genetics (246 citations) and Pulmonary and Respiratory Medicine (184 citations). L. E. Shepherd has collaborated with scholars based in Canada, United States and Belgium. Frequent co-authors include J. N. Ingle, Dongsheng Tu, H. B. Muss, Michael Palmer, Kathleen I. Pritchard, Nicholas J. Robert, Silvana Martino, Stephen Couban, Michael Crump and Joseph L. Pater. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Cancer Research, Blood and Cancers.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact